Phase 2 study of first-line bevacizumab plus trebananib for mCRC

A phase 2 study in Australia found efficacy of first-line chemotherapy-free dual anti-angiogenic combination of bevacizumab plus trebananib for mCRC. Responses were durable and toxicity was manageable.